NLRP3 haploinsufficiency unmasks a compensatory NLRP1-NLRP3 interaction that drives accelerated aging in mice.

Inés Muela-Zarzuela, Elisabet Alcocer-Gómez, Juan M Suarez-Rivero, Evon Low, Abbas Ishaq, Mikel Azkargorta, Amparo Luque-Sierra, Franz Martin, Félix Elortza, Antonio Astorga-Gamaza, Rosa Antón, Sofía Bali, Joaquin Tamargo-Azpilicueta, Alejandra Guerra-Castellano, Irene Díaz-Moreno, Lukasz A Joachimiak, Javier Oroz, Jesús Ruiz-Cabello, Thomas von Zglinicki, Alberto Sanz, Mario D Cordero

Department of Molecular Biology and Biochemical Engineering, Universidad Pablo de Olavide, 41013 Seville, Spain. · pubmed

Paper

Abstract

The NLRP3 inflammasome has been implicated in a wide range of human diseases, including cardiovascular, metabolic, neurodegenerative (such as Alzheimer's disease), and other age-related conditions. This has positioned NLRP3 as a promising pharmacological target. Numerous studies have shown that complete NLRP3 ablation can prevent or mitigate these diseases. However, total elimination of NLRP3 is not a feasible therapeutic strategy for the millions of patients affected by these degenerative disorders. Consequently, drug development efforts have focused on partial inhibition of NLRP3 using compounds that reduce its expression or activity. Paradoxically, although many studies have used

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

NLRP3 haploinsufficiency triggers a compensatory NLRP1-NLRP3 interaction that accelerates aging in mice, suggesting that partial inhibition of NLRP3 may have detrimental pro-aging effects. This study is relevant because it addresses a fundamental mechanism of aging (inflammasome dysregulation) and challenges the prevailing therapeutic strategy of partial NLRP3 inhibition, highlighting potential risks in longevity interventions.

Author of this paper? Send a correction.